Healthcare provider profile · identity verified

Susannah Ehret, MD

Internal Medicine · LOS ANGELES, CA · NPI 1447251640

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	653	225
Levothyroxine Sodium	Levothyroxine Sodium	388	115
Gabapentin	Gabapentin	376	119
Rosuvastatin Calcium	Rosuvastatin Calcium	352	134
Losartan Potassium	Losartan Potassium	292	100
Amlodipine Besylate	Amlodipine Besylate	276	94
Lisinopril	Lisinopril	272	88
Metformin Hcl Er	Metformin Hcl	185	73
Alendronate Sodium	Alendronate Sodium	176	61
Albuterol Sulfate Hfa	Albuterol Sulfate	170	68
Trazodone Hcl	Trazodone Hcl	170	54
Omeprazole	Omeprazole	167	66
Atenolol	Atenolol	159	54
Pantoprazole Sodium	Pantoprazole Sodium	157	52
Azelastine Hcl	Azelastine Hcl	151	56
Simvastatin	Simvastatin	148	47
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	144	27
Prednisone	Prednisone	126	97
Hydrochlorothiazide	Hydrochlorothiazide	125	45
Meloxicam	Meloxicam	121	51
Metformin Hcl	Metformin Hcl	111	37
Furosemide	Furosemide	107	31
Mirtazapine	Mirtazapine	101	36
Potassium Chloride	Potassium Chloride	91	32
Triamcinolone Acetonide	Triamcinolone Acetonide	88	60
Metoprolol Tartrate	Metoprolol Tartrate	85	31
Pradaxa	Dabigatran Etexilate Mesylate	85	27
Montelukast Sodium	Montelukast Sodium	82	32
Duloxetine Hcl	Duloxetine Hcl	79	31
Tamsulosin Hcl	Tamsulosin Hcl	76	27
Ozempic	Semaglutide	74	11
Arexvy	Rsvpref3 Antigen/As01e/Pf	69	69
Clopidogrel	Clopidogrel Bisulfate	66	22
Carvedilol	Carvedilol	65	20
Wixela Inhub	Fluticasone Propion/Salmeterol	64	30
Escitalopram Oxalate	Escitalopram Oxalate	59	21
Sertraline Hcl	Sertraline Hcl	59	22
Estradiol	Estradiol	58	30
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	57	21
Bupropion Xl	Bupropion Hcl	56	19
Glipizide	Glipizide	52	19
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	50	18
Ondansetron Hcl	Ondansetron Hcl	49	17
Jardiance	Empagliflozin	48	18
Pravastatin Sodium	Pravastatin Sodium	48	17
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	46	suppressed
Acyclovir	Acyclovir	39	18
Famotidine	Famotidine	39	21
Fluoxetine Hcl	Fluoxetine Hcl	39	13
Spiriva Respimat	Tiotropium Bromide	38	14
Allopurinol	Allopurinol	36	14
Citalopram Hbr	Citalopram Hydrobromide	35	12
Glipizide Er	Glipizide	34	12
Metoprolol Succinate	Metoprolol Succinate	34	11
Terazosin Hcl	Terazosin Hcl	34	suppressed
Tizanidine Hcl	Tizanidine Hcl	34	12
Mupirocin	Mupirocin	33	21
Bisoprolol Fumarate	Bisoprolol Fumarate	31	suppressed
Propranolol Hcl	Propranolol Hcl	31	11
Tramadol Hcl	Tramadol Hcl	31	12
Pregabalin	Pregabalin	30	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	30	suppressed
Ibuprofen	Ibuprofen	29	13
Amoxicillin	Amoxicillin	28	suppressed
Finasteride	Finasteride	28	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	27	suppressed
Clobetasol Propionate	Clobetasol Propionate	26	16
Ibandronate Sodium	Ibandronate Sodium	25	suppressed
Ipratropium Bromide	Ipratropium Bromide	25	suppressed
Valacyclovir	Valacyclovir Hcl	25	suppressed
Adacel Tdap	Diph,pertuss(Acell),tet Vac/Pf	24	24
Fenofibrate	Fenofibrate	24	suppressed
Verapamil Er	Verapamil Hcl	24	suppressed
Ciclopirox	Ciclopirox	23	11
Lovastatin	Lovastatin	23	suppressed
Alvesco	Ciclesonide	22	11
Topiramate	Topiramate	22	suppressed
Humulin N	Insulin Nph Human Isophane	21	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	21	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	21	suppressed
Alprazolam	Alprazolam	20	suppressed
Colchicine	Colchicine	20	suppressed
Hydralazine Hcl	Hydralazine Hcl	20	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	20	suppressed
Clonidine Hcl	Clonidine Hcl	19	suppressed
Ezetimibe	Ezetimibe	18	suppressed
Nystatin	Nystatin	18	14
Paroxetine Hcl	Paroxetine Hcl	18	suppressed
Acetaminophen-Codeine	Acetaminophen With Codeine	17	suppressed
Naltrexone Hcl	Naltrexone Hcl	17	suppressed
Stiolto Respimat	Tiotropium Br/Olodaterol Hcl	17	suppressed
Veo Insulin Syringe	Syringe-Needle,insulin,0.5 Ml	17	suppressed
Cephalexin	Cephalexin	16	14
Doxycycline Monohydrate	Doxycycline Monohydrate	16	14
Raloxifene Hcl	Raloxifene Hcl	16	suppressed
Xarelto	Rivaroxaban	16	suppressed
Ketoconazole	Ketoconazole	15	suppressed
Mometasone Furoate	Mometasone Furoate	15	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	15	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	15	suppressed
Celecoxib	Celecoxib	14	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	14	suppressed
Metronidazole	Metronidazole	14	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	14	14
Veo Insulin Syringe	Syringe And Needle,insulin,1ml	14	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	14	suppressed
Fluticasone Propionate	Fluticasone Propionate	13	suppressed
Hydrocortisone	Hydrocortisone	13	suppressed
Lorazepam	Lorazepam	13	suppressed
Temazepam	Temazepam	13	suppressed
Breyna	Budesonide/Formoterol Fumarate	12	suppressed
Butalbital-Acetaminophen-Caffe	Butalb/Acetaminophen/Caffeine	12	suppressed
Prednisolone Acetate	Prednisolone Acetate	12	suppressed
Tadalafil	Tadalafil	12	suppressed
Dextroamphetamine-Amphet Er	Dextroamphetamine/Amphetamine	11	suppressed
Nifedipine Er	Nifedipine	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error